In patients with advanced SM, mostly in aggressive SM (ASM), SM with an associated hematologic neoplasm (SM‐AHN), or MC leukemia (MCL), additional genetic changes have been identified: mutations in TET2, SRSF2, ASXL1, or RUNX1, which might play a crucial role in the development of the variety of clinical outcomes and the aggressiveness of SM, and may represent new therapeutic targets.3 This evidence concerns the gene TET2 and systemic mastocytosis.